title: FDA advisers favor easing rosiglitazone restrictions.
authors.forename: Kate
authors.initials: K
authors.lastname: Traynor
mesh_terms: D026683:Advisory Committees / Q000331:legislation & jurisprudence / Q000592:standards*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000331:legislation & jurisprudence / Q000592:standards; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence / Q000592:standards*; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone